Key points from article :
Will Harborne, a British entrepreneur, has launched LongGame, a $40 million venture capital fund focused on investing in early-stage biotech companies aimed at extending healthy human life by over 10 years. The fund will prioritise areas like gene editing, stem cell therapies, and senolytics, targeting technologies that can address the root causes of ageing. Harborne’s background in crypto has shaped LongGame’s innovative funding approach, including leveraging decentralised science to democratise investment and enable liquidity in longevity research.
LongGame’s strategy emphasises affordability and accessibility, aiming to develop low-cost therapies that can be integrated into mainstream healthcare systems for broader societal benefits. The fund has already backed companies like Adaptyv Bio and Vincere Bio and plans to balance long-term life extension research with near-term commercialisation opportunities. This approach intends to create a cycle of revenue reinvestment to sustain radical ageing-related biotech innovations.
The team includes co-founders Chloe Northcott and Dr. Manish Chamoli, who brings over 15 years of ageing biology expertise. They collaborate with advisors like Sebastian Brunemeier to identify impactful investment opportunities. Harborne stresses that funding, not regulation, is the main obstacle in the longevity field, with LongGame aiming to fill this gap by supporting scalable and meaningful approaches.
Published insights into the fund’s mission highlight its commitment to pushing boundaries in ageing biology while ensuring equitable access to these advancements.
